黄芪甲苷Ⅳ治疗心力衰竭的临床前证据和可能的机制：一项系统综述和Meta分析

LI Xing-xing; LI Dong; CUI Xiao-yun; ZHOU Kun; LIU Jing; LU Jin-jin; WU Yang; LIN Qian; LI Yan

doi:10.1007/s11655-023-3636-x

Your Location：

Home >

Browse articles >

黄芪甲苷Ⅳ治疗心力衰竭的临床前证据和可能的机制：一项系统综述和Meta分析

Evidence-Based Integrative Medicine | Updated：2023-06-27

- 黄芪甲苷Ⅳ治疗心力衰竭的临床前证据和可能的机制：一项系统综述和Meta分析
- Astragaloside Ⅳ for Heart Failure: Preclinical Evidence and Possible Mechanisms, A Systematic Review and Meta-Analysis^*
- 中国结合医学杂志（英文版） 2023年29卷第7期页码：626-633
- Affiliations：
  
  1.Department of Cardiology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing (100078), China
  2.Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing (100700), China
- Author bio：
  
  Dr. LI Yan, E-mail: erzitaba@163.com
- Funds：
  
  National Natural Science Foundation of China(81973622);Capital's Funds for Health Improvement and Research(2020-2-4201)
- DOI：10.1007/s11655-023-3636-x
  中图分类号：
- 纸质出版日期：2023-07，
  
  网络出版日期：2023-05-18，
  
  录用日期：2023-03-01
Scan for full text
黄芪甲苷Ⅳ治疗心力衰竭的临床前证据和可能的机制：一项系统综述和Meta分析[J]. 中国结合医学杂志（英文版）, 2023,29(7):626-633.

LI Xing-xing, LI Dong, CUI Xiao-yun, et al. Astragaloside Ⅳ for Heart Failure: Preclinical Evidence and Possible Mechanisms, A Systematic Review and Meta-Analysis^*[J]. Chinese Journal of Integrative Medicine, 2023,29(7):626-633.
黄芪甲苷Ⅳ治疗心力衰竭的临床前证据和可能的机制：一项系统综述和Meta分析[J]. 中国结合医学杂志（英文版）, 2023,29(7):626-633. DOI： 10.1007/s11655-023-3636-x.

LI Xing-xing, LI Dong, CUI Xiao-yun, et al. Astragaloside Ⅳ for Heart Failure: Preclinical Evidence and Possible Mechanisms, A Systematic Review and Meta-Analysis^*[J]. Chinese Journal of Integrative Medicine, 2023,29(7):626-633. DOI： 10.1007/s11655-023-3636-x.

摘要

目的:

探讨黄芪甲苷Ⅳ (Astragaloside astragaloside Ⅳ

AS-Ⅳ) 对心力衰竭 (Heart failure

HF) 的心脏保护作用.

方法:

通过检索PubMed、EMBASE、Cochrane、Web of Science、SinoMed、万方数据库、维普数据库、中国知网

得到从建库至2021年11月1日发表的探究AS-Ⅳ对HF治疗作用的动物实验. 检测指标包括左室射血分数 (left ventricular ejection fraction

LVEF) 、左室缩短分数 (left ventricular fractional shortening

LVFS) 、左室舒张末期内径 (left ventricular end-diastolic dimension

LVEDD) 、左室收缩末期内径 (left ventricular end-systolic dimension

LVESD) 、左心室重量与体重之比 (left ventricular weight-to-body weight

LVW/BW) 和B型脑钠肽 (B-type brain natriuretic peptide

BNP) . 根据Cochrane手册进行过偏倚风险分析从而评估纳入研究的质量. 使用Stata 13.0进行Meta分析.

结果:

21篇文章涉及558只动物被纳入. 与对照组相比

AS-Ⅳ增加了LVEF (MD=6.97

95% CI=5.92至8.03

0.05

固定效应模型) 和LVFS (MD=7.01

95%CI=5.84至8.81

0.05

固定效应模型)

降低了LVEDD (MD=–4.24

95%CI=-4.74至-3.76

0.05

随机效应模型) 和LVESD (MD=–4.18

95%CI=-5.26至-3.10

0.05

随机效应模型) . 此外

AS-Ⅳ还降低了BNP和LVW/BW水平 (MD=-9.18

95%CI=–14.13至–4.22

0.05

随机效应模型; MD=–1.91

95%CI=–2.42至–1.39

0.05

随机效应模型) .

结论:

AS-Ⅳ是一种很有前途的HF治疗药物. 然而

这一结论需要未来在临床中得到证实.

Abstract

Objective:

To explore the cardioprotective effects of astragaloside Ⅳ (AS-Ⅳ) in heart failure (HF).

Methods:

PubMed

Excerpta Medica Database (EMBASE)

Cochrane Library

Web of Science

Wanfang Database

Chinese Bio-medical Literature and Retrieval System (SinoMed)

China Science and Technology Journal Database (VIP)

and China National Knowledge Infrastructure (CNKI) were searched from inception to November 1

2021 for animal experiments to explore AS-Ⅳ in treating HF in rats or mice. The left ventricular ejection fraction (LVEF)

left ventricular fractional shortening (LVFS)

left ventricular end-diastolic dimension (LVEDD)

left ventricular end-systolic dimension (LVESD)

left ventricular weight-to-body weight (LVW/BW) and B-type brain natriuretic peptide (BNP) were recorded. The qualities of included studies were assessed by the risk of bias according to the Cochrane handbook. Meta-analysis was performed using Stata 13.0.

Results:

Twenty-one articles involving 558 animals were considered. Compared with the control group

AS-Ⅳ improved cardiac function

specifically by increasing LVEF (mean difference (MD)=6.97

95% confidence interval (CI)=5.92 to 8.03

0.05; fixed effects model) and LVFS (MD=7.01

95% CI=5.84 to 8.81

0.05; fixed effects model)

and decreasing LVEDD (MD=–4.24

95% CI=–4.74 to –3.76

0.05; random effects model) and LVESD (MD=–4.18

95% CI=–5.26 to –3.10

0.05; fixed effects model). In addition

the BNP and LVW/BW levels were decreased in the AS-Ⅳ treatment group (MD=–9.18

95% CI=–14.13 to –4.22

0.05; random effects model; MD=–1.91

95% CI=–2.42 to –1.39

0.05; random effects model).

Conclusions:

AS-Ⅳ is a promising therapeutic agent for HF. However

this conclusion needs to be clinically validated in the future.

关键词

黄芪甲苷Ⅳ心力衰竭临床前证据系统综述

Keywords

astragalosideⅣheart failurepre-clinical evidencesystematic review

references

More>

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Approach to Assess Adequacy of Acupuncture in Randomized Controlled Trials: A Systematic Review

Intelligent Chinese Medicine: A New Direction Approach for Integrative Medicine in Diagnosis and Treatment of Cardiovascular Diseases^*

Shexiang Tongxin Dropping Pill Allieviates Heart Failure via Extracellula Matrix-Receptor Interaction Pathways Based on RNA-Seq Transcriptomics and Experimental Studies^*

Therapeutic Efficacy of Shexiang Baoxin Pill Combined with Exercise in Patients with Heart Failure with Preserved Ejection Fraction: A Single-Center, Double-Blind, Randomized Controlled Trial